Thought Leadership
At NDA our experts stay abreast with the evolving environment and the new regulatory requirements that it gives rise to. One of the results of these activities is a stream of articles, commentaries and white papers that we publish for the benefit of our clients and followers. It captures the state of the art of our industry today.
We call it Thought Leadership.
Articles and White Papers
Service:
Scientific:
Sort by:
All services
Development Strategy
Medical Devices
Pharmacovigilance
NDA Advisory Board
Strategic Communications
Regulatory
Quality & Compliance
All expertise
Oncology
Vaccine
Immunogenicity
HTA
In-Vitro Diagnostics
Non-Clinical
Cell and Gene Therapy
Biostatistics
Cardiology
ATMP
Rare Disease
Market Access
CMC
Clinical
Paediatric
Acceleration Strategies
Medical Devices
Quality
Patient Safety
17-05-2023
Why is a potency assay important for cell and gene therapy products?
Paula Salmikangas, Björn Carlsson, Christophe Klumb and Tatiana Reimer together with Prof. Steffen Thirstrup published an article in Frontiers in Medicine, Regulatory Science.
24-03-2021
Addressing the challenges of GTMPs
Dr Paula Salmikangas and Dr Björn Carlsson address the challenges related to the development of novel gene therapies.
23-09-2020
Integrated product development for ATMPs
In this article, published in the September issue of MedNous, Claes and Paula discuss why an integrated product development strategy for ATMPs is essential to meet both regulatory and HTA requirements.
02-02-2019
Design and optimisation of a quality target product profile for ATMPs
The QTPP is an inherent element of product development for an MAA, yet it is perhaps more familiar for those developing conventional pharmaceuticals
02-08-2018
CAR T-Cells for Cancer Immunotherapy – Moving Target for Industry?
This article discusses the product-and patient-related variables that may pose challenges for the industry and developers both from the scientific and regulatory perspective.
02-07-2018
How to commercialise ATMPs in the EU
This article addresses recent findings from the EMA PRIME scheme and provides information about procedural updates and evolving guidance in the ATMP area.